Medical device companies and investigators often begin with a clear clinical or product development objective, but turning it into a feasible study brings another level of complexity. The research must generate scientifically robust evidence, remain practical to execute and meet regulatory requirements. Early decisions around design, endpoints, submissions and site strategy can shape what follows. “Medical device studies are rarely ‘one size fits all’,” says Marc Bosiers, CEO, Rede Optimus. “Regulatory requirements and operational realities can vary significantly between countries and sites.” Rede Optimus brings clinical, regulatory and study management expertise together to turn complex requirements into executable studies. It has supported more than 140 clinical studies across over 20 countries. Its hands-on model keeps project managers and CRAs close to sponsors and sites. The company can manage a complete clinical investigation or provide individual services, with scope, milestones and fixed budgets agreed upfront. Building the Study Around the Question The work often begins before a protocol exists. An investigator may bring a clinical question without defined endpoints or an execution plan. Rede Optimus helps structure the idea by clarifying what the study needs to answer, which endpoints can generate meaningful evidence, how many patients and sites may be required and which regulatory pathway applies..

Stem cell storage at birth is a once-in-a-lifetime decision. Parents want the confidence that their child’s cells will remain clinically viable if ever needed. That trust depends on more than storage—it relies on medical experience, transparent operations, full licensing, and a proven record of therapeutic use. With more than 25 years of continuous operation and its oldest German facility, Vita34, nearing 30 years, FamiCord is Europe’s largest family stem cell banking group and the only publicly listed company in this field. It gives families assurance through transparency and long-term realibility, confirming FamiCord as the best choice in Europe for stem cell banking. The company offers a complete system that guides parents from collection to processing, long-term preservation, and eventual release of cord blood and perinatal tissue for treatment. Each step is anaged under strict medical and regulatory standards to ensure cells retain therapeutic potential, with a documented chain of custody, validated cold-chain transport, and laboratory checks for viability and sterility. This matters because gobally, hematopoietic stem cells from cord blood have been used in more than 60,000 transplants across 80 diseases, and 158 ongoing clinical trials continue to refine indications and delivery. Regenerative medicine is rapidly opening new uses for cord blood and cord tissue. Beyond hematology, cord blood contains immuno- and neuroactive cell subsets under study for autism, cerebral palsy, neurodegeneration, autoimmune and cardiovascular conditions, with 140 active clinical trials worldwide. “We are not simply a bank of stem cells. A bank only stores the material, but it is really about whether you ever can deploy the stem cells for a transplant or therapy. We are glad we have that experience,” says Tomasz Baran, MD, Chief Medical Officer. Strength Through Structure and Innovation FamiCord operates under licensed medical service frameworks across major European markets, ensuring full national regulatory compliance and external oversight. About half of its 15 laboratories hold AABB accreditation, one of two international standards for cord blood standards in banking. As EBMT member, FamiCord aligns with Europe’s bone marrow transplant and cell therapies community. Scale, application experience, and transparency are core strengths. As Europe’s only publicly listed stem cell bank, FamiCord provides families and partners with full transparency into its financial stability—aligned with the long-term horizons of stem cell preservation. In 2024 FamiCord expanded beyond Europe, opening its first lab in Dubai-quickly earning AABB accreditation, applying standards established in European operations. Regional names such as Smart Cells (UK and Dubai) and Vita 34 (DACH region) now operate under the FamiCord umbrella, helping clinicians and parents recognize that a single, regulated organization stands behind the service..

As the race to develop genetic medicines intensifies, the tools required to engineer them must evolve just as rapidly. DNA is at the core of every advanced therapy—yet traditional plasmid-based production methods are increasingly inadequate to meet the speed, precision, and purity required by modern developers. Syngoi, a pioneering biotech company based in Europe, is redefining how DNA is manufactured. Its fully enzymatic, cGMP-compliant platform produces linear, synthetic DNA (oDNA), eliminating the biological constraints of bacterial fermentation. This approach enables faster, cleaner, and more scalable production—while also optimizing and customizing synthetic DNA for a wide variety of therapeutic approaches in the development of genetic medicines. “Our goal was to create a platform that unlocks the full potential of synthetic DNA for therapeutic applications,” says Dr. Julen Oyarzabal, Syngoi’s Chief Scientific Officer and co-founder. “By moving away from plasmid DNA and embracing a fully cell-free, enzymatic process rooted in synthetic biology, we’re giving developers the speed, purity, and customization their projects need to reach the patient while maintaining the highest standards of quality and performance.” Moving Beyond Plasmid Constraints Plasmid DNA (pDNA) has long served as the standard template for genetic medicine development. But its drawbacks—long production timelines, reliance on bioreactors, and biological contaminants like endotoxins and antibiotic resistance genes—now pose growing obstacles to efficient progress. Syngoi’s technology addresses these limitations directly. Its cell-free platform delivers linear synthetic DNA at both research and clinical scales in as little as five working days. The resulting DNA is highly pure, free from bacterial elements, and ready to integrate into mRNA manufacturing, genome editing, and other genetic medicine workflows. Flexible, Custom DNA for Every Application Syngoi’s system is designed to support diverse therapeutic needs. DNA is available in single- or double-stranded formats and can be enhanced with customizable adaptor sequences—short, non-coding oligonucleotides that improve performance across key steps such as transfection, delivery, and transcription..